Drug intelligence / Profile preview

TG1050

Development stage: Phase 2
Lead developer: Transgene
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**TG1050** is a therapeutic vaccine developed by Transgene for chronic hepatitis B (CHB), consisting of a replication-defective adenovirus serotype 5 (Ad5) vector that expresses hepatitis B virus (HBV) polymerase, core antigen domains, and surface antigen domains. It induces HBV-specific T-cell responses, including IFN-γ producing cells targeting multiple HBV antigens, while demonstrating a favorable safety profile in phase 1/1b trials with single and multiple doses up to 10^11 virus particles in virally suppressed CHB patients on nucleoside analogs. Early efficacy signals include reductions in HBsAg and HBcrAg levels. T101 is its Chinese counterpart developed by Transgenomic.

Other names: T101T-101T 101

Targets

HBV Pol (Hepatitis B virus polymerase)HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on TG1050.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TG1050.

Explore the full profile